1. Home
  2. GNPX vs DRCT Comparison

GNPX vs DRCT Comparison

Compare GNPX & DRCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GNPX
  • DRCT
  • Stock Information
  • Founded
  • GNPX 2009
  • DRCT 2018
  • Country
  • GNPX United States
  • DRCT United States
  • Employees
  • GNPX N/A
  • DRCT N/A
  • Industry
  • GNPX Biotechnology: Pharmaceutical Preparations
  • DRCT Computer Software: Programming Data Processing
  • Sector
  • GNPX Health Care
  • DRCT Technology
  • Exchange
  • GNPX Nasdaq
  • DRCT Nasdaq
  • Market Cap
  • GNPX 10.8M
  • DRCT 8.8M
  • IPO Year
  • GNPX 2018
  • DRCT 2022
  • Fundamental
  • Price
  • GNPX $6.64
  • DRCT $0.36
  • Analyst Decision
  • GNPX
  • DRCT Strong Buy
  • Analyst Count
  • GNPX 0
  • DRCT 1
  • Target Price
  • GNPX N/A
  • DRCT $6.00
  • AVG Volume (30 Days)
  • GNPX 1.7M
  • DRCT 5.5M
  • Earning Date
  • GNPX 11-14-2025
  • DRCT 11-06-2025
  • Dividend Yield
  • GNPX N/A
  • DRCT N/A
  • EPS Growth
  • GNPX N/A
  • DRCT N/A
  • EPS
  • GNPX N/A
  • DRCT N/A
  • Revenue
  • GNPX N/A
  • DRCT $36,459,000.00
  • Revenue This Year
  • GNPX N/A
  • DRCT $16.81
  • Revenue Next Year
  • GNPX N/A
  • DRCT $35.28
  • P/E Ratio
  • GNPX N/A
  • DRCT N/A
  • Revenue Growth
  • GNPX N/A
  • DRCT N/A
  • 52 Week Low
  • GNPX $6.51
  • DRCT $0.28
  • 52 Week High
  • GNPX $140.00
  • DRCT $6.59
  • Technical
  • Relative Strength Index (RSI)
  • GNPX 63.07
  • DRCT 52.20
  • Support Level
  • GNPX $7.71
  • DRCT $0.33
  • Resistance Level
  • GNPX $9.89
  • DRCT $0.37
  • Average True Range (ATR)
  • GNPX 1.15
  • DRCT 0.04
  • MACD
  • GNPX 0.53
  • DRCT 0.01
  • Stochastic Oscillator
  • GNPX 50.54
  • DRCT 60.09

About GNPX Genprex Inc.

Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.

About DRCT Direct Digital Holdings Inc.

Direct Digital Holdings Inc is an end-to-end, full-service programmatic advertising platform focused on providing advertising technology, data-driven campaign optimization, and other solutions to underserved and less efficient markets on both the buy-side and sell-side of the digital advertising ecosystem. The company operates two reportable segments: sell-side advertising, which includes the results of Colossus Media, and buy-side advertising, which includes the results of Orange 142 and Huddled Masses. All of the company's revenues are attributed to the United States.

Share on Social Networks: